乳腺癌患者与COVID-19疫苗接种后腋窝淋巴结特征:按影像学方法概述当前证据
该非系统性叙述性综述汇总了腋窝超声、乳腺MRI和18F-FDG PET/CT在乳腺癌诊断与COVID-19疫苗接种后腋窝淋巴结特征方面的现有证据,指出疫苗接种后最常见的超声表现为弥漫性皮质增厚,而转移淋巴结多表现为局灶性皮质增厚和脂肪门消失;接种后淋巴结肿大报告频率因影像方法而异,并受注射部位、疫苗类型、接种与成像间隔等因素影响。
要点
- 超声上疫苗接种后淋巴结多为弥漫性皮质增厚,转移淋巴结多为局灶性皮质增厚和脂肪门消失。
- MRI和18F-FDG关于腋窝淋巴结形态学特征的当前证据尚缺,有建议疫苗相关淋巴结肿大更可能位于2级和3级淋巴结。
- 需记录注射部位、疫苗类型和接种日期以改善图像解读并指导后续处理。
核心结论
- 乳腺癌诊断时与COVID-19疫苗接种后的淋巴结特征存在差异,但需记录注射部位、疫苗类型和接种日期以改善解读并指导后续处理。
研究设计与样本
- 非系统性叙述性综述,纳入描述乳腺癌患者与COVID-19疫苗接种后腋窝淋巴结特征的各影像方法(腋窝超声、乳腺MRI和18F-FDG PET/CT)研究。
关键影像表现/征象
- 超声上疫苗接种后最常见的特征是淋巴结弥漫性皮质增厚,而转移淋巴结表现为最可疑的局灶性皮质增厚和脂肪门消失。
- 原文提及有建议疫苗相关淋巴结肿大更可能出现在2级和3级淋巴结,而非转移淋巴结。
诊断标准与关键数值
- COVID-19疫苗接种后淋巴结肿大的报告频率:超声49%至85%,乳腺MRI 29%,18F-FDG PET/CT 14.5%至53.9%。
临床应用与阅片要点
- 临床信息包括注射部位、疫苗类型和接种日期需要记录,以改善图像解读并指导后续处理步骤。
- 可能影响疫苗接种后淋巴结肿大出现或程度的因素包括注射部位、疫苗类型(mRNA与载体)、接种与成像之间的时间间隔(天)、既往COVID-19肺炎病史以及第一剂与第二剂疫苗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Axillary lymph node characteristics on axillary ultrasound (US), breast MRI and 18F-FDG PET/CT are relevant at breast cancer diagnosis. Axillary lymphadenopathy after COVID-19 vaccination has been frequently reported. This may cause a diagnostic dilemma, particularly in the ipsilateral axilla in women who have a either a recent diagnosis of breast cancer or a history of breast cancer. This review provides an overview of the current evidence regarding axillary lymph node characteristics at breast cancer diagnosis versus "post-COVID-19 vaccination".
METHODS: A non-systematic narrative review was performed. Studies describing axillary lymph node characteristics per imaging modality (axillary US, breast MRI and 18F-FDG PET/CT) in breast cancer patients versus post-COVID-19 vaccination were selected and used for the current study.
RESULTS: The morphologic characteristics and distribution of abnormal nodes on US may differ from the appearance of metastatic adenopathy since diffuse cortical thickening of the lymph nodes is the most observed characteristic after vaccination, whereas metastases show as most suspicious characteristics focal cortical thickening and effacement of the fatty hilum. Current evidence on MRI and 18F-FDG on morphologic characteristics of axillary lymphadenopathy is missing, although it was suggested that vaccine related lymphadenopathy is more likely to be present in level 2 and 3 nodes than metastatic nodes. Reported frequencies of lymphadenopathy post-COVID-19 vaccination range from 49% to 85% (US), 29% (breast MRI) and 14.5% to 53.9% (18F-FDG PET/CT). Several factors may impact the presence or extent of lymphadenopathy post-COVID-19 vaccination: injection site, type of vaccine (i.e., mRNA versus vector), time interval (days) between vaccination and imaging, previous history of COVID-19 pneumonia, and first versus second vaccine dose.
CONCLUSION: Although lymph node characteristics differ at breast cancer diagnosis versus post-COVID-19 vaccination, clinical information regarding injection site, vaccine type and vaccination date needs to be documented to improve the interpretation and guide treatment towards the next steps of action.
引用
- van Nijnatten, Jochelson, Lobbes, et al. Axillary lymph node characteristics in breast cancer patients versus post-COVID-19 vaccination: Overview of current evidence per imaging modality. Eur J Radiol. 2022. PMID: 35512513. doi:10.1016/j.ejrad.2022.110334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。